Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 2/2014

Open Access 01-12-2014 | Meeting abstract

Deep TCR repertoire sequencing reveals relative change in peanut specific clonotype in subjects undergoing rush oral immunotherapy

Authors: Philippe Bégin, Kari C Nadeau

Published in: Allergy, Asthma & Clinical Immunology | Special Issue 2/2014

Login to get access

Excerpt

Oral immunotherapy is an emerging therapy currently under investigation for the treatment of food allergy [1]. Underlying mechanisms are thought to involve a switch in the food specific T cell response from Th2 to either Th1, Tr1 and/or Treg. It is unknown whether this change in response results from re-education of existing pathological food-specific T cells or from their replacement by new healthy T cells (change of guard hypothesis). …
Literature
1.
Bégin P, Chinthrajah RS, Nadeau KC: Oral immunotherapy for the treatment of food allergy. Hum Vaccin Immunother. 2014, 10: 8-CrossRef
2.
Bégin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, Trela A, Tavassoli M, Hoyte E, O’Riordan G, Blakemore A, Seki S, Hamilton RG, Nadeau KC: Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy, Asthma & Clinical Immunology. 2014, 10: 7-10.1186/1710-1492-10-S1-A7.CrossRef
Metadata
Title
Deep TCR repertoire sequencing reveals relative change in peanut specific clonotype in subjects undergoing rush oral immunotherapy
Authors
Philippe Bégin
Kari C Nadeau
Publication date
01-12-2014
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1710-1492-10-S2-A53

Other articles of this Special Issue 2/2014

Allergy, Asthma & Clinical Immunology 2/2014 Go to the issue

Meeting abstract

Anaphylaxis associated with folic acid: domestic case review

Meeting abstract

Mediators of allergic rhinitis: optimization of RNA isolation, reverse transcription, and qPCR protocols

Meeting abstract

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria

Meeting abstract

Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada

Meeting abstract

C-CARE: comparing three years of anaphylaxis in children treated at the Montreal Children’s Hospital

Meeting abstract

Growth factors regulate proteinase activated receptor – 2 (PAR-2) on airway epithelium